Clinical Trial Update: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the combination of carboplatin, paclitaxel, cetuximab, and erlotinib for metastatic or recurrent head and neck squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cetuximab (cetuximab)
• ERLOTINIB (Erlotinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED